The Caisse Nationale de l’Assurance Maladie (CNAM), the French national health insurance fund, has joined forces with L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the body with responsibility for the safety of medicines in France. They have launched a joint venture: a scientific interest group (GIS) in pharmacoepidemiology and epidemiology of medical devices.
The new group, called Epi-Phare, is a public “structure of expertise” which will help identify risks earlier, based on real data, and contribute to decision making in health technology. 25 experts from the Epidemiology Pole of the ANSM and the Department of Public Health Studies of the CNAM make up Epi-Phare, and bring vast experience from medical practice, statistics and pharmacy to bear on their challenges.
The ANSM report:
“On the proposal of the GIS management, and validation of its scientific council, the work program aims to carry out studies on the use of health products, targeting in particular misuse, populations considered fragile (elderly, infants and children). children, pregnant women, disadvantaged populations …) or new drugs, as well as studies on the safety of drugs and medical devices.”